Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Feb 26

PMID 38407352

Authors

Mari Nakazawa

Guilherme Harada

Paola Ghanem

Adrian Bubie

Lesli A Kiedrowski

Joseph C Murray

Kristen A Marrone

Susan C Scott

Stefanie Houseknecht

Christina J Falcon

Patrick Evans

Josephine Feliciano

Christine L Hann

David S Ettinger

Kellie N Smith

Valsamo Anagnostou

Patrick M Forde

Julie R Brahmer

Benjamin Levy

Alexander Drilon

Vincent K Lam

Affiliations

Soon will be listed here.

Abstract

Significance: In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. Our findings that certain ALK variants and co-mutations are associated with differential survival and specific TKI-relevant resistance patterns highlight potential molecular underpinnings of the heterogenous response to ALK TKIs and nominate biomarkers that may inform patient selection for first-line and consolidative therapies.

References

Nagasaka M, Ou S . Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. J Thorac Oncol. 2022; 17(2):182-185. DOI: 10.1016/j.jtho.2021.11.010. View

Yoda S, Lin J, Lawrence M, Burke B, Friboulet L, Langenbucher A . Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018; 8(6):714-729. PMC: 5984716. DOI: 10.1158/2159-8290.CD-17-1256. View

Calles A, Riess J, Brahmer J . Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. Am Soc Clin Oncol Educ Book. 2020; 40:372-384. DOI: 10.1200/EDBK_280795. View

Shaw A, Yeap B, Mino-Kenudson M, Digumarthy S, Costa D, Heist R . Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26):4247-53. PMC: 2744268. DOI: 10.1200/JCO.2009.22.6993. View

Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C . Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist. 2020; 25(8):702-711. PMC: 7418350. DOI: 10.1634/theoncologist.2020-0088. View

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2007; 8(1):11-23. DOI: 10.1038/nrc2291. View

Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R . Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018; 29(10):2068-2075. PMC: 6225899. DOI: 10.1093/annonc/mdy333. View

Lin J, Riely G, Shaw A . Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017; 7(2):137-155. PMC: 5296241. DOI: 10.1158/2159-8290.CD-16-1123. View

Hsu K, Huang Y, Tseng J, Chen K, Ku W, Su K . High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019; 127:37-43. DOI: 10.1016/j.lungcan.2018.11.021. View

10.

Gainor J, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R . Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016; 6(10):1118-1133. PMC: 5050111. DOI: 10.1158/2159-8290.CD-16-0596. View

11.

Shih D, Nayyar N, Bihun I, Dagogo-Jack I, Gill C, Aquilanti E . Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020; 52(4):371-377. PMC: 7136154. DOI: 10.1038/s41588-020-0592-7. View

12.

Pallavajjala A, Haley L, Stinnett V, Adams E, Pallavajjala R, Huang J . Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Hum Pathol. 2022; 126:63-76. DOI: 10.1016/j.humpath.2022.05.001. View

13.

Wang W, Xu C, Chen Y, Liu W, Zhong L, Chen F . mutations predict for poor survival in rearrangement lung adenocarcinoma patients treated with crizotinib. J Thorac Dis. 2018; 10(5):2991-2998. PMC: 6006073. DOI: 10.21037/jtd.2018.04.98. View

14.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

15.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

16.

. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831. PMC: 5611790. DOI: 10.1158/2159-8290.CD-17-0151. View

17.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J . Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015; 21(17):4014-21. DOI: 10.1158/1078-0432.CCR-15-0016. View

18.

Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T . Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023; 13(7):1556-1571. PMC: 11024958. DOI: 10.1158/2159-8290.CD-22-1420. View

19.

Heuckmann J, Balke-Want H, Malchers F, Peifer M, Sos M, Koker M . Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012; 18(17):4682-90. DOI: 10.1158/1078-0432.CCR-11-3260. View

20.

Schneider J, Lin J, Shaw A . ALK-positive lung cancer: a moving target. Nat Cancer. 2023; 4(3):330-343. PMC: 10754274. DOI: 10.1038/s43018-023-00515-0. View